002166 莱茵生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.1142.6637.2466.4744.850
总资产报酬率 ROA (%)1.3621.8174.6343.6892.985
投入资产回报率 ROIC (%)1.6222.1435.6074.7373.431

边际利润分析
销售毛利率 (%)28.59724.41530.79929.80427.875
营业利润率 (%)11.9847.92018.11114.42712.677
息税前利润/营业总收入 (%)12.8919.42417.57616.84014.430
净利润/营业总收入 (%)9.3726.58313.44212.45510.997

收益指标分析
经营活动净收益/利润总额(%)83.02275.37894.04478.51368.373
价值变动净收益/利润总额(%)3.51143.12016.60811.17417.724
营业外收支净额/利润总额(%)-6.719-1.683-6.442-0.011-0.385

偿债能力分析
流动比率 (X)1.6542.0322.5131.4811.506
速动比率 (X)0.8581.2221.6350.9140.928
资产负债率 (%)37.10030.72330.12641.67642.795
带息债务/全部投入资本 (%)21.27915.72613.99621.545--
股东权益/带息债务 (%)345.297509.482577.684335.584382.954
股东权益/负债合计 (%)165.365220.366228.331137.582132.287
利息保障倍数 (X)7.7605.76331.3306.9768.011

营运能力分析
应收账款周转天数 (天)107.907106.84276.23478.1750.000
存货周转天数 (天)386.451302.341298.241334.0400.000